Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.82 USD
Change Today -0.03 / -1.62%
Volume 609.5K
As of 3:19 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$1.86
Previous Close
$1.85
Day High
$1.87
Day Low
$1.81
52 Week High
03/9/15 - $2.94
52 Week Low
05/26/15 - $1.65
Market Cap
328.3M
Average Volume 10 Days
1.1M
EPS TTM
$-0.50
Shares Outstanding
180.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

132 Employees
Last Reported Date: 03/12/15
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $594.0K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $545.8K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $544.4K
Compensation as of Fiscal Year 2014.

cti biopharma corp (CTIC) Key Developments

CTI BioPharma Corp. Announces Findings from an Investigator-Sponsored Phase 2 Trial in Patients with Either Primary Acute Myeloid Leukemia

CTI BioPharma Corp. announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54% in elderly patients with AML with 45% of patients achieving durable complete responses (CR). AML is the most common acute leukemia affecting adults, and its incidence increases with age. AML may develop from the progression of other diseases, such as MDS, which is a blood cancer that also affects the bone marrow and leads to a decrease in circulating red blood cells. Tosedostat is a potential first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Final results presented at EHA show that responding patients had a significant improvement in overall survival based on response rates compared to non-responding patients (p=0.018). In the intent-to-treat population (ITT), the ORR was 54% with CR observed in 45% of patients (n=15/33). In the responding patients, the median time for achieving best response was 74 days (range: 22-145 days) and 55% (n=10/18) were still in remission after a median follow-up of 319 days. Safety analysis show that tosedostat in combination with LDAC was generally well tolerated. The primary adverse events observed were pneumonitis (12%), cardiac (6%), brain hemorrhage (3%), and asthenia (3%).

Cell Therapeutics and Baxter Bioscience Report Positive Patient Reported Outcomes from Phase 3 Study of Pacritinib as Treatment for Myelofibrosis

Cell Therapeutics and Baxter International's BioScience business reported positive patient-reported outcome data for pacritinib from the Phase 3 PERSIST-1 study, a randomized, controlled Phase 3 registration-directed trial comparing the efficacy and safety of pacritinib to the best available therapy (BAT) in 327 patients with myelofibrosis, regardless of the patients' platelet counts. Myelofibrosis is a rare blood cancer associated with significantly reduced quality of life and shortened survival. The companies said that results from the study show a significant reduction in the Total Symptom Score (the proportion of patients with a 50% or greater reduction in TSS from baseline to Week 24), and in each individual common disease-related symptom, from baseline to Week 24, in patients treated with pacritinib compared to BAT (exclusive of a JAK inhibitor).

CTI BioPharma Corp. Amends Loan Agreement

CTI BioPharma Corp. announced that it has amended its existing loan agreement with Hercules Technology Growth Capital Inc. Pursuant to the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding immediately prior to closing of the amendment. On June 9, 2015, approximately $6.2 million (less fees and expenses) was funded, thereby resulting in a current outstanding principal balance under the facility of $20.0 million. The remaining $5.0 million is available for borrowing at CTI BioPharma's option through June 30, 2016, subject to no event of default under the facility and the satisfaction of the following two conditions: receipt by Hercules on or prior to December 31, 2015 of satisfactory evidence that CTI BioPharma has achieved full patient enrollment for the PERSIST-2 Phase III clinical trial for pacritinib and receipt by Hercules on or prior to June 30, 2016 of satisfactory evidence that CTI BioPharma has achieved positive phase III data in connection with such clinical trial.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $1.82 USD -0.03

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $3.05 USD -0.095
Cytokinetics Inc $6.55 USD +0.16
Evotec AG €3.50 EUR +0.12
Navidea Biopharmaceuticals Inc $1.70 USD -0.02
Rigel Pharmaceuticals Inc $3.06 USD +0.08
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book 18.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.